跳至主要内容
临床试验/NL-OMON54056
NL-OMON54056招募中不适用

The Effect of a Multimodal Lifestyle Intervention on Chronic Fatigue in Patients with Inflammatory Bowel Disease - Multi-IBD

eids Universitair Medisch Centrum0 个研究点目标入组 106 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
106

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • o Adults (>=18 years old);
  • o Established IBD diagnosis (Crohn*s disease, Ulcerative colitis, or
  • IBD-unclassified);
  • o Biochemical remission (fecal calprotectin <=150 mcg/g);
  • o Clinically significant fatigue (VAS 4-8 out of 10);
  • o Willing and able to attend digital group sessions as a part of the
  • intervention.

排除标准

  • o Documented comorbidities such as severe cardiac failure (classified as NYHA 3-
  • 4), chronic kidney disease, myelodysplastic syndrome, Chronic Obstructive
  • Pulmonary Disease (COPD), inherited metabolic diseases (e.g., phenylketonuria,
  • mitochondrial or uric acid cycle pathologies), diabetes type 1;
  • o Documented history of malignancy within the last three years before inclusion
  • except for dermatological cancers such as basal cell carcinoma or squamous cell
  • o Documented history of psychiatric diseases, eating disorders or addiction.
  • Exception: patients with a history of depression and/or under treatment with
  • antidepressants; however, at inclusion these patients must have a Hospital
  • Anxiety Depression Scale (HADS) score <11 for the depression subscale;
  • o Documented familial hypercholesterolemia;
  • o Diabetes type 2 treated with insulin or other medications such as
  • sulfonylureas, glinides, alpha-glucosidase inhibitors, etc. The only exception
  • is biguanides*metformin.;
  • o BMI <18.5 or >35 kg/m2;
  • o Clinically significant anemia (Hb <7.0 mmol/l in females, Hb <8.0 mmol/l in
  • males) with the exception of marginal normocytic or macrocytic anemia (MCV >100
  • fL and Hb >7.0 mmol/L for females and Hb >8.0 mmol/L for males) as a result of
  • IBD-therapy related myelosuppression;
  • o Vitamin B12 deficiency (defined as a concentration below the lower reference
  • range expressed in units that are used by the laboratory where the test has
  • been performed);
  • o Folic acid deficiency (defined as a concentration below the lower reference
  • range expressed in units that are used by the laboratory where the test has
  • been performed);
  • o Iron deficiency (defined as ferritin <30 µg/l);
  • o Vitamin D deficiency (<30 nmol/l);
  • o History of prior bariatric surgery or upper gastrointestinal surgery such as
  • Roux-Y reconstruction or (partial) gastrectomy due to benign or malignant
  • pathologies;
  • o Pregnancy or active breastfeeding;
  • o Unwillingness to follow the lifestyle program, i.e. people that do not want
  • to eat fish, vegans;
  • o Any change in systemic IBD-related medication in the last three months from
  • the start of the intervention. Changes in medication dose are allowed up to one
  • month before the start of the intervention. Exception: changing the route of
  • administration (e.g., switching from intravenous infliximab to subcutaneous
  • infliximab) or change in therapy due to side effects such as an allergic
  • reaction or cutaneous conditions.
  • o Recent major surgery, e.g. laparotomy in the last four weeks;
  • o Recent >2-week long hospitalization (in the last four weeks);
  • o Unable to speak and understand Dutch language;
  • o Participation in another study with lifestyle intervention or active
  • consultation with a lifestyle coach on patient*s initiative;
  • o Previous participation in the IBD-tailored program by Voeding Leeft.

研究者

相似试验